A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2019-03-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability and assess preliminary
efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Incyte Biosciences International Sàrl Incyte Europe Sàrl